Carmine Therapeutics is an Esco Ventures X company pioneering a powerful new class of drugs based on engineered red blood cells extracellular vesicles (RBCEVs), founded by Esco Ventures and Professors Harvey Lodish, Minh Le and Jiahai Shi. Carmine focuses on developing a therapeutic platform that would address some of the technological unmet needs related to the delivery of next generation therapies such as nucleic acid-based therapeutics.
Esco Medical is automating and standardizing IVF embryology lab with workflows to improve clinical outcomes and enhance patient satisfaction. We are developing the world’s first open protocol automated vitrification system and novel modalities for embryo selection.
Esco Medical ApS
Precision Medicine Diagnostics
Pre-term birth is the leading cause of neonatal mortality and morbidity, with over 15 million babies born pre-term every year. The annual direct healthcare economic burden in the US alone is an estimated $30 billion. Reducing pre-term birth rates, therefore, is an urgent unmet medical and economic need globally.
An Esco Ventures founded portfolio company, Carmentix, aims to reduce pre-term births around the world by commercializing a novel test for early prediction weeks or months before symptoms occur, in order to enable early prophylaxis with existing medical interventions. Together with its collaborators, Carmentix launched the world’s largest multi-center, prospective clinical study in pre-term birth in 2018.
Carmentix Pte Ltd
This is truly biology’s century. Esco Ventures X, the venture creation arm of Esco Ventures, builds biotech startups at the intersection of unmet medical needs, novel biological insights and platform technologies. We operate in Singapore and China, and have recently established an office in Cambridge, Massachusetts, USA. In June 2018, Esco Ventures X launched a first-in-Asia Fellowship program, the Esco Ventures Fellowship. It is focused on biotech platforms, and aims to groom aspiring bio-entrepreneurs.
Esco Ventures Pte Ltd